Mergers & Acquisitions ·
Curaleaf challenges Aurora's rejection of its enhanced $5.00 per share proposal
CURLDCuraleaf Holdings, Inc.
Curaleaf Holdings responded to Aurora Cannabis' board recommending shareholders reject Curaleaf's enhanced hostile bid, which values the company at $5.00 per share. The offer represents an 86% premium to Aurora's unaffected 30-day volume-weighted average price and a 217% ex-cash premium. Curaleaf criticized Aurora for granting diligence access to unnamed parties while denying it, arguing the board is obstructing value-maximizing engagement. Curaleaf remains ready to engage in a constructive due diligence process. The company operates as a leading international provider of consumer and medical cannabis products.